Category Archives: Corporate News

Medizone International Announces a Retirement from the Board of Directors

June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) the developer of AsepticSure, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that Daniel D. Hoyt has retired from the Board of Directors.

Effective June 21, 2017, Daniel D. Hoyt will retire from the Board and all positions within the company.

“On behalf of our employees, the board, and shareholders, I want to thank Dan for his leadership and commitment to the Company. Since January 2002, Dan has been an active member of the board and he has given a full measure to support our business and our people through the amazing journey of the company,” commented David Esposito. “We wish Dan all the best as he moves into this next chapter of life with his family.”

Medizone continues to execute on plans to establish AsepticSure as a superior solution worldwide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness. The near term priority market is the United States while the Company continues to support sales and distribution channels in several other markets across the globe.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Conference Call: TODAY – 4:00 – 5:00 PM EST

Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, will be hosting a conference call on Wednesday, June 21, 2017, from 4:00 – 5:00 PM EST to provide an update on global commercial operations and address questions from investors.

The call-in details:

  • Toll-Free in North America: 800 681 1924
  • Toll call from outside North America: +1 303 223 4393
  • A replay of the conference call will be available for seven days after the call.

The conference call and replay are open to all interested parties. Replay call in information:

  1. Toll-Free in North America: 800 633 8284 reservation #21854308
  2. Toll call from outside North America: +1 402 977 9140 #21854308
  3. Materials to support the call ARE NOW AVAILABLE – BELOW.

SLIDES FOR MEDIZONE CONFERENCE CALL – PDF

Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

AsepticSure® Receives Full Approval of International Electrical Safety Standards

AsepticSure approval of international safety standards clears path for global commercialization

 

KALAMAZOO, Mich., June 21, 2017 – Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, a revolutionary disinfection technology that combines ozone and hydrogen peroxide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparedness, announced today that the Company has received full electrical safety approval for all models of AsepticSure.

The testing and approval was administered by QPS Evaluation Services, a nationally and internationally accredited independent third-party testing, certification and field evaluation body headquartered in Toronto, Canada. The approval means that AsepticSure has achieved full compliance with the applicable international safety standards which provide a baseline requirement that must be met in order to pursue marketing in all jurisdictions, including Canada, USA, South America, EU, Asia, and the Middle East. Although Medizone will be required to apply for a separate approval in each country, compliance with these international safety standards will greatly facilitate this process.

“We are very pleased to announce that AsepticSure technology has received full approval for electrical safety,” said Dr. Michael Shannon, President and Director of Medical Affairs of Medizone International. “With respect to future marketing endeavors in North America, third-party certification of electrical products is mandated by law; without such certification, marketing would not be permitted. Approval of our AsepticSure system is a major step forward towards full commercialization.”

The achievement of full compliance with the relevant international safety standards provides the framework for detailed manufacturing specifications that will be incorporated in the Company’s expanded manufacturing plans.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Expands Patent Coverage for AsepticSure

AsepticSure receives US Patent for Food-Handling Facility Disinfectant

 

June 20, 2017 – Medizone International, Inc. (OTCQB: MZEI) (Kalamazoo, MI) today announces the United States Patent and Trademark Office has agreed to grant a patent for Food-Handling Facility Disinfectant for AsepticSure (US Patent 9,616,144).

“Our team our researchers continues to demonstrate the broad utility of AsepticSure in a number of commercial applications,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The granting of this patent helps to strengthen our intellectual property to ensure protected access to these large market opportunities.”

The food services industry is a significant market opportunity for the Company. The patent for Food-Handling Facility Disinfectant adds to a strong portfolio of IP covering hospital disinfection, bioterrorism counter measures, and sports equipment and facility disinfection.

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Medizone International Registered to Exhibit AsepticSure® at the Military Health System’s Vendor Day

AsepticSure’s registration at the Military Health System’s Vendor Day presents opportunity to demonstrate several applications for the Department of Defense

KALAMAZOO, Mich., June 20, 2017 — Medizone International, Inc. (OTCQB: MZEI) announces the Company has registered to attend the Military Health System’s Vendor Day on September 27, 2017 at the Defense Medical Logistics Center on Fort Detrick in Frederick, MD. Vendor Day presents a unique opportunity to interact directly with a large number of government agencies and to demonstrate the utility of AsepticSure®.

The Military Health System Vendor Day is a cooperative venture by the military service medical logistics agencies, located on Fort Detrick in Frederick, MD. The agencies involved are: Defense Health Agency Medical Logistics Division (DHA MEDLOG), U.S. Army Medical Research and Materiel Command (USAMRMC), U.S. Army Medical Materiel Agency (USAMMA), Naval Medical Logistics Command (NMLC), Air Force Medical Operations Agency (AFMOA), U.S. Marine Corp Systems Command (MARCORSYSCOM). The focus of the event is to assist the services’ medical logistics agencies with strategic market analysis of products and technologies that may be applicable to the austere medical environments.

“Given the broad range of applications for AsepticSure to the military, including hospital disinfection, bioterrorism countermeasures, and food handling facility disinfection, we are excited about engaging with the many agencies represented at the Military Health System’s Vendor Day,” commented David A. Esposito, Chairman and interim CEO of Medizone International. “This event builds on the work already underway to gain acceptance of AsepticSure in multiple government agencies.”

Medizone International plans to attend the event with a full display of the AsepticSure system and with several members from the sales and engineering teams to address any potential inquiries from attendees. The Company is planning an invitation outreach to prospects in advance of the meeting to ensure maximum attendance and engagement at the exhibit booth.
About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:
John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

Update Medizone International Conference Call: Wednesday, June 21st from 4:00 – 5:00 PM EST

Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, will be hosting a conference call on Wednesday, June 21, 2017, from 4:00 – 5:00 PM EST to provide an update on global commercial operations and address questions from investors.

The call in details will support the call:

  • Toll-Free in North America: 800 681 1924
  • Toll call from outside North America: +1 303 223 4393
  • A replay of the conference call will be available for seven days after the call.

 

The conference call and replay are open to all interested parties. Replay call in information:

  1. Toll-Free in North America: 800 633 8284 reservation #21854308
  2. Toll call from outside North America: +1 402 977 9140 #21854308
  3. Materials to support the call will be made available on the website prior to the start of the call.

Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

Medizone International Expands Sales Potential by Addressing the Sports Equipment Industry with AsepticSure

Recent study highlights the potential of AsepticSure to provide superior cleaning to athletic equipment – A critical need for players, coaches and families

 

KALAMAZOO, Mich., June 15, 2017 – Medizone International, Inc. (OTCQB: MZEI) announces the completion of a study that demonstrates the efficacy of AsepticSure in killing microorganisms found on athletic equipment such as hockey equipment and other protective gear.  This recent scientific evidence in support of AsepticSure opens up the athletic equipment industry within professional, collegiate, and organized sports at all levels as a viable commercial segment in the United States and other key markets in the world.

In this most recent study, conducted by Medizone researchers in Canada, AsepticSure was demonstrated to be an effective means of eliminating microorganisms on commonly used athletic equipment. This study confirms the findings from initial studies supporting the use of AsepticSure as a general environmental disinfectant. AsepticSure’s proprietary technology that combines oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone is safe and effective in support of general cleaning of athletic equipment.

“As part of our robust research and development program, this recent study supports another key advancement in the development of AsepticSure,” commented Michael Shannon, M.A., M.Sc., M.D., President and Director of Medical Affairs for Medizone International. “Our research team continues to be active in discovering new areas of unmet need to demonstrate the positive impact of AsepticSure. We have plans to continue to transfer our current research initiatives into immediate commercial opportunities for AsepticSure.”

The athletic equipment industry is a massive industry with over $65 billion in annual sales in the US alone. The utilization of AsepticSure to support general cleaning of athletic equipment represents an immediate market opportunity for Medizone International. The company is actively pursuing a wide range of business development initiatives with both cleaning companies that service the athletic industry and initiating direct contact with professional and collegiate sports teams.

“We are continually impressed with the leadership of Dr. Shannon and our team of talented researchers for continuing to identify new areas of use for AsepticSure,” said David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The athletic equipment cleaning industry is a significant, routine expense for professional and collegiate sports team.  In addition, any parent who shuttles kids around from football, hockey or some other sport would appreciate a technology that could provide superior cleaning to the current century old process. We see significant business potential for Medizone in this large market. The opportunity for ongoing, repeat customers is a key part of our commercial plan.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:
www.medizoneint.com
Email: [email protected]

 

Medizone International Expands Global Sales Potential by Addressing the Death Care Industry with AsepticSure®

Recent study highlights the potential of AsepticSure to provide superior cleaning to mortuary preparation areas within funeral homes

 

KALAMAZOO, Mich., June 8, 2017 – Medizone International, Inc. (OTCQB: MZEI) announces the completion of a study that demonstrates the efficacy of AsepticSure® in killing microorganisms found in preparation rooms within funeral homes. This recent scientific evidence in support of AsepticSure opens up the death care industry as a viable commercial segment in the United States and other key markets in the world.

In this most recent study, conducted by Medizone researchers in Canada, AsepticSure was demonstrated to be an effective means of eliminating microorganisms in the critical need area of preparation rooms within funeral homes. This study confirms the findings from initial studies supporting the use of AsepticSure as a general environmental disinfectant. AsepticSure’s proprietary technology that combines oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone is safe and effective in support of general disinfection of preparation rooms.

“This recent study supports another key advancement in the development of AsepticSure,” commented Michael Shannon, M.A., M.Sc., M.D., President and Director of Medical Affairs for Medizone International. “Our research team continues to be active in discovering new areas of unmet need to demonstrate the positive impact of AsepticSure. We look forward to transferring our current research initiatives into immediate commercial opportunities for AsepticSure.”

The death care industry is a $16 billion industry in the U.S. alone with over 20,000 funeral homes and 100,000 employees. The utilization of AsepticSure to support general disinfection of preparation rooms represents an immediate market opportunity for Medizone International. The company is actively pursuing a wide range of business development initiatives with the major publicly traded companies that are leading innovation in the death care industry in the United States.

“We are thankful to Dr. Shannon and our team of talented researchers for continuing to identify new areas of use for AsepticSure,” said David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “The death care industry is ready for innovative tools like AsepticSure to improve cleaning techniques in dealing with healthcare waste in challenging areas like preparation rooms. We see significant business potential for Medizone in this fast growing market.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The company developed the AsepticSure system to combine oxidative compounds (O3 and H202) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

For press information on Medizone International, please contact:

John Pentony, Investor and Media Relations
Medizone International, Inc.
T: 01 269-202-5020
E: [email protected]

For more information, visit:

www.medizoneint.com

Email: [email protected]

Medizone International Conference Call: Wednesday, June 21st from 4:00 – 5:00 PM EST

Medizone International, Inc. (OTCQB: MZEI), the developer of AsepticSure®, today announced that the company will host a conference call on Wednesday, June 21, 2017, from 4:00 – 5:00 PM EST to provide an update on global commercial operations and address questions from investors.

Call in details and presentation materials will be made available on the Company’s website prior to the call (www.medizoneint.com).

A replay of the conference call will be available for seven days after the call. The conference call and replay are open to all interested parties.

Please submit questions to be addressed on the call to John Pentony, Investor Relations ([email protected]).

Medizone International Expands Commercial Team to Address Growing Global Opportunity in Bioterrorism Countermeasures and Public Health Preparedness

Internationally recognized expert Brad Goble to lead Medizone’s efforts to capitalize on government efforts to address bioterrorism countermeasures and public health risks

 

Medizone International, Inc. (OTCQB: MZEI) announces the appointment of bioterrorism expert Brad Goble to lead the company’s efforts to engage with government agencies and organizations tasked with coordinating global resources. He will be responsible for the advancement of AsepticSure® as a key component of programs in support of bioterrorism countermeasures and public health preparedness.

“As governments and affiliated agencies across the globe prepare to combat the growing risks of bioterrorism and major health outbreaks, AsepticSure is ideally positioned to help address these efforts,” commented David A. Esposito, Chairman of the Board and interim CEO of Medizone International. “We continue to look for talented executives with significant commercial experience in contracting with governments and organizations with global reach in the area of biodefense and public health preparedness. Brad Goble has decades of experience working directly with governments and organizations to address these major global concerns and we are pleased he will be leading our efforts to capitalize on the opportunity.”

AsepticSure has demonstrated, in well-designed clinical studies, to successfully eliminate known surrogates for Anthrax, Ebola, SARS, and MERS-CoV. The unique combination of low dose hydrogen peroxide and ozone is well ahead of other technologies in this area and can play a critical role in addressing the need for preparedness for government agencies and coordinated efforts around the world.  Medizone International has solid intellectual property rights in several countries in support of bioterrorism countermeasures.

Goble has played a major role in consulting with governments and public health preparedness agencies around the world, especially in the days after September 11, 2001. “He has had a seat at the table for major initiatives addressing bioterrorism and public health concerns around Ebola and SARS and is relied on for his expertise across the globe,” adds Esposito.

Goble is a native of Toronto, Canada and holds an honors degree in Economics and Commerce from the Royal Military College of Canada and a Master of Business Administration from Queen’s University.

“I am very excited to work with the Medizone team as we support the increasing demand for technology to address the major concerns of bioterrorism and public health outbreaks,” commented Goble. “The AsepticSure system has the potential to play a major role in assisting integrated response teams and well-funded programs across the globe to combat bioterrorism. I look forward to leveraging my existing relationships to open doors that could place AsepticSure on the forefront of meeting the global need for new tools to address these threats.”

About Medizone International, Inc.

Founded initially in 1986 to develop treatments for lipid-enveloped viruses, Medizone International, Inc. shifted focus in 2007 to develop a superior disinfectant technology. The Company developed the AsepticSure system to combine anti-oxidant gases (O3 and H202) to produce unique free radicals (H2O3 known as trioxidane) with higher anti-oxidant potential than ozone or hydrogen peroxide alone. After securing broad IP protection for the use of trioxidane for both healthcare facility disinfecting systems and bioterrorism applications, the Company released its AsepticSure system for use in Canada, and several other global markets.

Safe Harbor Statement

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including the risk that government and international agencies and organizations may not adopt our system, global economic conditions generally, government regulation, manufacturing and marketing risks, adverse publicity risks, risks associated with our entry into the U.S. and other markets, expansion and operations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

Investor and Media Relations

Medizone International, Inc.

T: 269-202-5020

E: [email protected]